MktsMarkets

Aldeyra Therapeutics, Inc.
NASDAQ: ALDXKey statistics
ALDX News
Stories mentioning ALDX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,410 | 4,304 | 5,431 | 8,505 | 7,423 | 14,629 | 12,442 | 14,970 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (3,547) | (6,668) | (8,001) | (10,169) | (10,427) | (16,577) | (16,138) | (18,008) |
| Interest Income | 563.00 | 682.00 | 789.00 | 872.00 | 981.00 | 1,240 | 1,504 | 1,638 |
| Interest Expense | 478.00 | |||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (3,453) | (6,462) | (7,688) | (9,767) | (9,930) | (15,808) | (15,113) | (16,848) |
| Earnings Per Share (Basic) | (0.06) | (0.11) | (0.13) | (0.16) | (0.17) | (0.27) | (0.25) | (0.28) |
| Earnings Per Share (Diluted) | (0.06) | (0.11) | (0.13) | (0.16) | (0.17) | (0.27) | (0.25) | (0.28) |
| Weighted Average Shares Outstanding (Basic) | 60,319 | 60,057 | 60,127 | 60,046 | 59,887 | 59,485 | 59,530 | 59,414 |
| Weighted Average Shares Outstanding (Diluted) | 60,319 | 60,057 | 60,127 | 60,046 | 59,887 | 59,485 | 59,530 | 59,414 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ALDX
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) is a stock listed on the Nasdaq Stock Market under the ticker symbol ALDX. It last traded at $0.6400 (Oct 23, 2026, 3:52 PM ET), down 1.5% on the day. That gives Aldeyra Therapeutics a market capitalisation of $38.9M.
Over the past 52 weeks ALDX has traded between $0.6300 and $5.93.
For the quarter ended Mar 31, 2026 it reported a net loss of $3.5M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$3.5M |
| Dec 31, 2025 | — | -$6.5M |
| Sep 30, 2025 | — | -$7.7M |
| Jun 30, 2025 | — | -$9.8M |
From Aldeyra Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…